IN THE NEWS: Dr. Jeffrey Zonder co-authors paper published in the New England Journal of Medicine

The New England Journal of Medicine

Congratulations to Jeffrey Zonder, M.D., leader of the Multiple Myeloma and Amyloidosis Multidisciplinary Team at Karmanos Cancer Institute. Dr. Zonder co-authored a paper that was recently published by The New England Journal of Medicine. Titled “Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis,” the paper includes the results of a randomized trial, which led to the first FDA approval of any therapy for AL amyloidosis: Daratumumab-FasPro + CyBorD. Three former Karmanos fellows are also co-authors.

Click here to view the article.